Insider Transactions in Q2 2023 at Vertex Pharmaceuticals Inc (VRTX)
Insider Transaction List (Q2 2023)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 15
2023
|
Stuart A Arbuckle EVP, COO |
SELL
Open market or private sale
|
Direct |
8,603
-13.2%
|
$3,002,447
$349.0 P/Share
|
|
Jun 15
2023
|
Stuart A Arbuckle EVP, COO |
BUY
Exercise of conversion of derivative security
|
Direct |
8,603
+11.66%
|
$1,608,761
$187.53 P/Share
|
|
May 30
2023
|
Stuart A Arbuckle EVP, COO |
SELL
Open market or private sale
|
Direct |
82
-0.14%
|
$26,978
$329.82 P/Share
|
|
May 30
2023
|
Kristen Ambrose SVP & Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
289
-4.06%
|
$95,081
$329.82 P/Share
|
|
May 08
2023
|
Bastiano Sanna EVP, Cell & Genetic Therapies |
SELL
Open market or private sale
|
Direct |
2,850
-8.17%
|
$997,500
$350.0 P/Share
|
|
May 08
2023
|
Jeffrey M Leiden Executive Chairman |
SELL
Open market or private sale
|
Direct |
1,125
-3.08%
|
$392,625
$349.0 P/Share
|
|
May 05
2023
|
Bastiano Sanna EVP, Cell & Genetic Therapies |
SELL
Open market or private sale
|
Direct |
422
-1.2%
|
$147,700
$350.03 P/Share
|
|
May 05
2023
|
Jeffrey M Leiden Executive Chairman |
SELL
Open market or private sale
|
Direct |
879
-1.18%
|
$306,771
$349.84 P/Share
|
|
May 03
2023
|
Bastiano Sanna EVP, Cell & Genetic Therapies |
SELL
Open market or private sale
|
Direct |
2,781
-3.7%
|
$976,131
$351.02 P/Share
|
|
May 03
2023
|
Jeffrey M Leiden Executive Chairman |
SELL
Open market or private sale
|
Direct |
4,508
-3.71%
|
$1,577,800
$350.45 P/Share
|
|
May 02
2023
|
Bastiano Sanna EVP, Cell & Genetic Therapies |
SELL
Open market or private sale
|
Direct |
1,622
-1.37%
|
$569,322
$351.74 P/Share
|
|
May 02
2023
|
Jeffrey M Leiden Executive Chairman |
SELL
Open market or private sale
|
Direct |
6,450
-4.59%
|
$2,263,950
$351.05 P/Share
|
|
May 02
2023
|
Sangeeta N. Bhatia Director |
SELL
Open market or private sale
|
Direct |
580
-2.33%
|
$201,840
$348.36 P/Share
|
|
May 01
2023
|
Suketu Upadhyay Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,168
+29.99%
|
-
|
|
May 01
2023
|
Diana Mckenzie Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,168
+30.97%
|
-
|
|
May 01
2023
|
Diana Mckenzie Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
1,449
-50.24%
|
-
|
|
May 01
2023
|
Alan M Garber Director |
BUY
Grant, award, or other acquisition
|
Direct |
584
+8.27%
|
-
|
|
May 01
2023
|
Sangeeta N. Bhatia Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,168
+18.32%
|
-
|
|
May 01
2023
|
Lloyd Carney Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,168
+18.01%
|
-
|
|
Apr 27
2023
|
Reshma Kewalramani CEO & President |
SELL
Open market or private sale
|
Direct |
3,317
-0.86%
|
$1,124,463
$339.44 P/Share
|
|
Apr 13
2023
|
Bruce I Sachs Director |
SELL
Bona fide gift
|
Direct |
1,210
-2.94%
|
-
|
|
Apr 12
2023
|
Bastiano Sanna EVP, Cell & Genetic Therapies |
SELL
Open market or private sale
|
Direct |
7,567
-5.6%
|
$2,466,842
$326.53 P/Share
|
|
Apr 12
2023
|
Bruce I Sachs Director |
SELL
Open market or private sale
|
Direct |
21,300
-12.78%
|
$6,943,800
$326.53 P/Share
|
|
Apr 12
2023
|
Bruce I Sachs Director |
BUY
Exercise of conversion of derivative security
|
Direct |
21,300
+25.41%
|
$1,533,600
$72.14 P/Share
|
|
Apr 04
2023
|
Bastiano Sanna EVP, Cell & Genetic Therapies |
SELL
Open market or private sale
|
Direct |
522
-0.22%
|
$164,952
$316.59 P/Share
|